Stay updated with breaking news from Zyme Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual
Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer ® biologics and pre|CISION™ tumour targeted chemotherapies. The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance ...
ERS Genomics and ZeClinics Sign CRISPR/Cas9 License Agreement ZeClinics is applying CRISPR technology to create gene edited zebrafish disease models ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and ZeClinics, a contract research organization using zebrafish to carry out services focused on analyzing the safety, efficacy and biomedical relevance of new compounds, today announced a non-exclusive license agreement granting ZeClinics access to ERS Genomics' CRISPR/Cas9 patent portfolio....
Avacta Group plc: Avacta announces AffyXell $7.3 Million Series A Financing Avacta's next generation cell and gene therapy joint venture with Daewoong Pharmaceutical secures Series A venture funding Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that AffyXell Therapeutics ("AffyXell"), the joint venture with Daewoong Pharmaceutical ("Daewoong"), has closed a Series A venture capital investment of $7.3 million to further develop its pipeline of next generation cell and gene therapies. AffyXell was established in January 2020 by Avact...
CN Bio's PhysioMimix Technology Receives FDA Recognition Represents the first co-published, peer-reviewed article between a microphysiological system provider and a regulator CN Bio, a leading developer of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research with the U.S. Food and Drug Administration (FDA) 1. The first co-published, peer-reviewed research paper between a commercial MPS provider and a regulator, demonstrates that data derived using CN Bio's proprietary...